Laboratory of Experimental Neuropathology, Instituto de Investigación Médica Mercedes y Martín Ferreyra, INIMEC-CONICET, Universidad Nacional de Córdoba, 5016 Córdoba, Argentina.
Neurobiol Aging. 2013 Nov;34(11):2525-37. doi: 10.1016/j.neurobiolaging.2013.04.021. Epub 2013 May 25.
A role of amyloid β (Aβ) peptide aggregation and deposition in Alzheimer's disease (AD) pathogenesis is widely accepted. Significantly, abnormalities induced by aggregated Aβ have been linked to synaptic and neuritic degeneration, consistent with the "dying-back" pattern of degeneration that characterizes neurons affected in AD. However, molecular mechanisms underlying the toxic effect of aggregated Aβ remain elusive. In the last 2 decades, a variety of aggregated Aβ species have been identified and their toxic properties demonstrated in diverse experimental systems. Concurrently, specific Aβ assemblies have been shown to interact and misregulate a growing number of molecular effectors with diverse physiological functions. Such pleiotropic effects of aggregated Aβ posit a mayor challenge for the identification of the most cardinal Aβ effectors relevant to AD pathology. In this review, we discuss recent experimental evidence implicating amyloid β precursor protein (APP) as a molecular target for toxic Aβ assemblies. Based on a significant body of pathologic observations and experimental evidence, we propose a novel pathologic feed-forward mechanism linking Aβ aggregation to abnormalities in APP processing and function, which in turn would trigger the progressive loss of neuronal connectivity observed early in AD.
淀粉样β(Aβ)肽聚集和沉积在阿尔茨海默病(AD)发病机制中的作用已被广泛接受。值得注意的是,聚集的 Aβ 诱导的异常与突触和神经突退化有关,与 AD 中受影响神经元的“退行性变”模式一致。然而,聚集的 Aβ的毒性作用的分子机制仍不清楚。在过去的 20 年中,已经鉴定出多种聚集的 Aβ 物质,并在各种实验系统中证明了它们的毒性特性。同时,已经表明特定的 Aβ 组装体可以相互作用并错误调节具有不同生理功能的越来越多的分子效应物。聚集的 Aβ 的这种多效性效应对鉴定与 AD 病理学相关的最重要的 Aβ 效应物提出了一个重大挑战。在这篇综述中,我们讨论了最近的实验证据,这些证据表明淀粉样前体蛋白(APP)是有毒的 Aβ 组装体的分子靶标。基于大量的病理观察和实验证据,我们提出了一个新的病理正反馈机制,将 Aβ 聚集与 APP 处理和功能的异常联系起来,这反过来又会引发 AD 早期观察到的神经元连接的渐进性丧失。